Medpage Today on MSN

Regulatory T-Cell Drug Promising for Eczema, With Hint for Asthma as Well

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...
The American Journal of Managed Care

Delgocitinib Is Redefining Chronic Hand Eczema Treatment: A Q&A With Raj Chovatiya, MD, PhD, MSCI

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.